

LASA SUPERGENERICS LIMITED

Corporate Office: B/207, "CITI POINT", Near Kohinoor Hotel, J.B. Nagar, Andheri (E), Mumbai -59 Tel: +91 22 4970 1092 • Email: info@lasalabs.com • Website: www.lasalabs.com

Statement of Unaudited Financial Results for the Quarter ended 30th September, 2018

(Rs. In Lakhs)

						(RS. IN Lakns
	Quarter ended			Half Year Ended		Year ended
Particulars						
	30.09.2018	30.06.2018	30.09.2017	30.09.2018	30.09.2017	31.03.2018
1	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1. INCOME	, ,			(**************************************	(01144411111111111111111111111111111111	(Flacitor)
a. Revenue from Operations	4,074.48	3,292.06	6,453.07	7,366.54	12,554.09	24,583.88
b. Other Income	103.98	101.88	135.21	205.86	265.08	348.66
Total Income	4,178.45	3,393.94	6,588.28	7,572.40	12,819.17	24,932.54
2. Expenses				- ,,	10,011	21,002.01
a. Cost of Materials consumed	1,784.48	1,701.13	5,209.43	3,485.61	8,365.17	17,205.86
b. Cost of Traded Goods	1,174.13	599.79	,	1,773.91	5,000	11,200,00
c. Change in Inventories of Finished Goods, Work-in-Progress						
and Stock in trade	41.35	(184.29)	(938.45)	(142.93)	(403.11)	(55.34)
d. Excise Duty on Sales (Refer Note No.2)			- 1	2.5	231.29	231.29
e. Employee benefits expenses	285.93	268.21	256.82	554.14	494.29	1,027.09
f. Finance costs (Refer Note No.3)	397.72	360.96	242.19	758.68	495.57	1,134.35
g. Depreciation & amortizations expenses	485.07	480.13	609.11	965.21	850.63	1,816.66
h. Other Expenses	443.80	385.65	621.65	829.44	1,032.09	2,049.30
Total Expenses (a to g)	4,612.48	3,611.58	6,000.75	8,224.06	11,065.94	23,409.21
Exceptional Items			-			:*:
3. Profit / (Loss) before tax (1-2)	(434.03)	(217.64)	587.54	(651.67)	1,753.24	1,523.33
4. Tax expense				` 1		1,-=1100
Current Tax			119.58	- 2	361.90	316.33
Deferred Tax	(307.10)	79.97	(398.42)	(227.13)	(180.30)	(26.99)
Short / Excess income tax provision for earlier years	70.69	-	- 1	70.69	1.73	==
5. Net Profit / (Loss) after tax (3-4)	(197.61)	(297.61)	866.37	(495.22)	1,569.91	1,233.99
6. Other Comprehensive Income					i	
Items that will not be reclassified into Profit or Loss	- 1				- 1	×
- Remeasurement of Defined Benefit Plans (Net of tax)	(0.38)	90	(0.36)	(0.38)	(1.11)	(1.42)
7. Total Comprehensive Income for the year (after tax) (5+6)					` 1	
	(197.99)	(297.61)	866.01	(495.60)	1,568.80	1,232.58
8. Paid-up Equity Share Capital (Face Value of Re. 10 /- each)			Ť		i	
	2,286.44	2,286.44	2,286.44	2,286.44	2,286.44	2,286.44
9. Other Equity excluding Revaluation reserve as per Balance				,	-,	_,,
Sheet	8,952.04	9,150.03	9,783.86	8,952.04	9,783.86	9,447.64
10. Earnings per Equity Share (of Rs. 10/- each)					,	-,
(a) Basic	(0.86)	(1.30)	3.79	(2.17)	6.87	5.40
(b) Diluted	(0.86)	(1.30)	3.79	(2.17)	6.87	5.40
See accompanying Notes to the Financial Results		` '[(====)	-,	0.10



CIN: U24233MH2016PLC274202

Factory & Regd. Office: C - 105, MIDC, Mahad, Dist - Raigad, Mahad - 402309 • Tel.: 02145-232101, 232202



LASA SUPERGENERICS LIMITED

Corporate Office: B/207, "CITI POINT", Near Kohinoor Hotel, J.B. Nagar, Andheri (E), Mumbai -59 Tel: +91 22 4970 1092 • Email: info@lasalabs.com • Website: www.lasalabs.com

LASA SUPERGENERICS LIMITED CIN: L24233MH2016PLC274202 Balance Sheet as at Sep 30, 2018

(Rs.	In L	akl	15)	í
------	------	-----	-----	---

Particulars	Note No.	As at	An -4	(Rs. In Lakhs		
rationals	Note No.	As at 30.09.2018	As at 30.06.2018	As at 30.09.2017	As at 31 March 2018	
ASSETS						
Non-current assets						
Property, Plant and Equipment		40.007.40				
	3	16,287.13	16,725.81	14,619.86	16,364.7	
Capital Work in Progress	3	695.79	695.79	1,699.98	698.7	
Intangible assets	3	602.54	599.39	517.47	599.3	
Intangible assets under development	3	25.10	25.10	23.85	25.1	
Financial Assets						
Non Current Investments	4	0.10	0.10	0.10	0.1	
Loans	5	72.82	72.41	70.85	71.8	
Other non-current assets	6	= 1		100	·	
Deffered Tax Assets	17	60.68	-			
		17,744.16	18,118.60	16,932.11	17,759.9	
Current assets						
Inventories	7	3,902.24	3,994.93	3,851.25	4,223.45	
Financial Assets		0,002.21	0,004.50	3,031.23	4,223.43	
Trade receivables	8	2,234.57	2,298.41	6,546.16	4,215.11	
Cash and cash equivalents	9	86.14	205.50	94.31		
Bank balances other than cash & cash equivalents	10	219.94	216.84	106.42	49.69	
Loans	11	5.00	5.60	0.60	213.79	
Other current assets	12	2,170.97	2,147.78		5.60	
	"	8,618.86	8,869.07	940.53 11,539.28	2,210.44 10,918.09	
		26,363.02	26,987.67	28,471.39	28,678.03	
QUITY AND LIABILITIES						
EQUITY						
Equity Share capital	13	2,286.44	2.286.44	2,286.44	2,286,44	
Other Equity	14	8,952.04	9,150.03	9,783.86	9,447.64	
		11,238.48	11,436.47	12,070.30	11,734.09	
LIADILITIES						
LIABILITIES			1			
Non-current liabilities						
Financial Liabilities		1				
Non Current Borrowings	15	6,547.15	6,417.04	4,591.84	6,026.99	
Provisions	16	29.30	25.35	27.86	23.75	
Deferred Tax Liabilities	17		246.55	14.03	166.58	
		6,576.46	6,688.94	4,633.73	6,217.33	
Current liabilities		- 1	1			
Financial Liabilities				, I		
Current Borrowings	18	2,310.22	2,339.25	2,219.52	2.002-04	
Trade payables	19	3,298.70	3,484.53	6,507.12	2,983:04	
Other financial liabilities	20	1,700.80	1,882.50	2,146.64	4,793.52	
Other current liabilities	21	568.69	711.37	231.79	1,711.89	
Provisions	22	306.12	151.41		815.33	
Current tax liabilities (net)	23	363.55	293.19	110.25	129.31	
, ,		8,548.08	8,862.25	552.03 11,767.35	293.52 10,726.61	
					10,120.01	
		26,363.02	26,987.67	28,471.39	28,678.03	

a Supergenerics Limited

ar Herlekar

irman & Managing Director) DIN 1587154

Place : Mumbai Date: 14th November,2018

CIN: U24233MH2016PLC274202

Factory & Regd. Office: C - 105, MIDC, Mahad, Dist - Raigad, Mahad - 402309 • Tel.: 02145-232101, 232202



LASA SUPERGENERICS LIMITED

Corporate Office: B/207, "CITI POINT", Near Kohinoor Hotel, J.B. Nagar, Andheri (E), Mumbai -59 Tel: +91 22 4970 1092 • Email: info@lasalabs.com • Website: www.lasalabs.com

Notes:

- 1) The Above Financial Results were reviewed by the audit committee of the board on 14th November, 2018 and approved by the Board of Directors of the company at their meting held on same date. The Statutory auditor have expressed on unmodified opinion. The review report has been filled with stock exchange and is available on the company's website. The Financial results have been prepared in accoradance with Ind As notified under the companies (Accounting Standards) Rule 2015.
- 2) Post implementation of Goods and Services Tax ("GST") in India with effect from 1st July, 2017, revenue are disclosed net of GST. Revenues for the earlier periods included excise duty which is now subsumed in the GST effective from 1st July 2017. Accordingly, revenues for the six month ended 30th September, 2018 are not comparable with previous comparative quater ended 30th September, 2017.
- 3) Finance cost includes Rs. 122.93 Lakhs being loss on account of foreign exchange fluctuations and Rs. 54.38 Lakhs being gain on account of foreign exchange fluctuations during the quarter ended 30th September, 2018 and 30th September, 2017 resepctively.
- 4) The Company has only one reportable segment i.e. Active Pharmaceutical Ingredients (API)
- 5) The pricing pressure of most of the raw materials in reporting quaters continued to increase and rached at a such extent that in order to utilise full capacity we may have taken biggest hit either on margins or in business front. Margins would have negative if the case be of full capacity utilisation, however to maintain reasonable balance on margins we decided to execute business upto extent which shall give atleast positive level of gross margins. Also one of the major reasons for declined top lines in drastic drop in universal demand for one of our top product. We are putting all our efforts to improve profitability in upcoming quaters.

6) Figures of previous period have been re-grouped / reclassified wherever necessary, to confirm to this period's classification.

For Lasa Supergenerics Limited

Omka Heriekar

Chairman & Managing Director

(DIN No. 01587154)

Place : Mumbai

Date: 14th November, 2018

CIN: U24233MH2016PLC274202

Factory & Regd. Office: C - 105, MIDC, Mahad, Dist - Raigad, Mahad - 402309 • Tel.: 02145-232101, 232202